Advanced medicines that demonstrate both strong clinical performance and benefits to patients.
Pipeline
90
+
compounds, devices or indications in development individually or under collaboration or license agreement
investment
$7.8
b
R&D investment in 2023
Commitment
50
+
programs are in mid and late-stage development
Novel
80
%
of compounds in clinical development with a novel mechanism of action
Pipeline
Updated November 15, 2024
Sort By
Focus Area
ABBV-319
BiologicC19 ∕ Steriod ADCPharmaceuticalOncology
ABBV-319 is a novel oncology first-in-class steroid-based ADC targeting CD19 that is anticipated to have robust single-agent activity and provide significant clinical benefit as combination therapy in a variety of B-cell malignancies, including DLBCL, FL and CLL.
TargetC19 ∕ Steriod ADC
Type of moleculeBiologic
ABBV-319 is a novel oncology first-in-class steroid-based ADC targeting CD19 that is anticipated to have robust single-agent activity and provide significant clinical benefit as combination therapy in a variety of B-cell malignancies, including DLBCL, FL and CLL.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Hematologic Tumors
N ∕ A
N ∕ Aphase1
phase1
Lutikizumab
BiologicImmunologyPharmaceuticalIL-1a ∕ 1b
Lutikizumab (ABT-981) is an IL-1a/1b antagonist being investigated for the treatment of hidradenitis suppurativa (HS) and ulcerative colitis.
TargetIL-1a ∕ 1b
Type of moleculeBiologic
Pronunciation
Lutikizumab (ABT-981) is an IL-1a/1b antagonist being investigated for the treatment of hidradenitis suppurativa (HS) and ulcerative colitis.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Hidradenitis Suppurativa
N ∕ A
N ∕ Aphase3
phase3
Ulcerative Colitis
N ∕ A
N ∕ Aphase2
phase2
ABBV-706
SEZ6 + Topo-1 ADCBiologicPharmaceuticalOncology
ABBV-706 is a seizure protein 6 homolog (SEZ6) targeted antibody-drug conjugate being investigated for the treatment of small cell lung cancer, central nervous system tumors and neuroendocrine carcinomas.
TargetSEZ6 + Topo-1 ADC
Type of moleculeBiologic
ABBV-706 is a seizure protein 6 homolog (SEZ6) targeted antibody-drug conjugate being investigated for the treatment of small cell lung cancer, central nervous system tumors and neuroendocrine carcinomas.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Small Cell Lung Cancer
N ∕ A
N ∕ Aphase1
phase1
ABBV-181 (budigalimab)
BiologicPharmaceuticalanti-PD1Oncology
ABBV-181 (budigalimab) is an anti-PD1 monoclonal humanized antibody that is being developed for combinations with other AbbVie molecules for solid tumors and hematologic malignancies.
Targetanti-PD1
Type of moleculeBiologic
ABBV-181 (budigalimab) is an anti-PD1 monoclonal humanized antibody that is being developed for combinations with other AbbVie molecules for solid tumors and hematologic malignancies.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Solid Tumors
N ∕ A
N ∕ Aphase2
phase2
ABBV-CLS-579
Small MoleculePharmaceuticalOncologyPTPN2 ∕ N1
ABBV-CLS-579 is being investigated as a monotherapy and in combination with a PD-1 inhibitor for the treatment of patients with metastatic or locally advanced solid tumor cancer.
Calico is responsible for research and early development and will advance collaboration projects into Phase 2a, including ABBV-CLS-579. AbbVie will continue to support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities.
TargetPTPN2 ∕ N1
Type of moleculeSmall Molecule
ABBV-CLS-579 is being investigated as a monotherapy and in combination with a PD-1 inhibitor for the treatment of patients with metastatic or locally advanced solid tumor cancer.
Calico is responsible for research and early development and will advance collaboration projects into Phase 2a, including ABBV-CLS-579. AbbVie will continue to support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Solid Tumors
N ∕ A
N ∕ Aphase1
phase1
ABBV-CLS-484
Small MoleculePharmaceuticalOncologyPTPN2 ∕ N1
ABBV-CLS-484 is being investigated as a monotherapy and in combination with a PD-1 inhibitor for the treatment of patients with metastatic or locally advanced solid tumor cancer.
Calico is responsible for research and early development of ABBV-CLS-484, and will advance collaboration projects into Phase 2a. AbbVie will continue to support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities.
TargetPTPN2 ∕ N1
Type of moleculeSmall Molecule
ABBV-CLS-484 is being investigated as a monotherapy and in combination with a PD-1 inhibitor for the treatment of patients with metastatic or locally advanced solid tumor cancer.
Calico is responsible for research and early development of ABBV-CLS-484, and will advance collaboration projects into Phase 2a. AbbVie will continue to support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities.
IMGN-151 is a folate receptor alpha-targeting biparatropic antibody drug conjugate (ADC) being investigated in ovarian and endometrial cancers.
TargetFR-alpha + DM21 maytansinoid
Type of moleculeBiologic
IMGN-151 is a folate receptor alpha-targeting biparatropic antibody drug conjugate (ADC) being investigated in ovarian and endometrial cancers.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Ovarian Cancer
N ∕ A
N ∕ Aphase1
phase1
Endometrial Cancer
N ∕ A
N ∕ Aphase1
phase1
ABBV-969
BiologicPSMA ∕ STEAP1 ADCPharmaceuticalOncology
ABBV-969 is an antibody-drug conjugate (ADC) targeting Prostate-Specific Membrane Antigen (PSMA) and six transmembrane epithelial antigen of the prostate 1 (STEAP1), being investigated to treat metastatic castration-resistant prostate cancer (mCRPC).
TargetPSMA ∕ STEAP1 ADC
Type of moleculeBiologic
ABBV-969 is an antibody-drug conjugate (ADC) targeting Prostate-Specific Membrane Antigen (PSMA) and six transmembrane epithelial antigen of the prostate 1 (STEAP1), being investigated to treat metastatic castration-resistant prostate cancer (mCRPC).
ABBV-303 is a novel c-Met targeting multi-specific immune cell engager therapy incorporating Dragonfly Therapeutics’ TriNKET® technology. ABBV-303 is being investigated for the treatment of solid tumors.
Targetc-Met
Type of moleculeBiologic ∕ Multi-specific Antibody
ABBV-303 is a novel c-Met targeting multi-specific immune cell engager therapy incorporating Dragonfly Therapeutics’ TriNKET® technology. ABBV-303 is being investigated for the treatment of solid tumors.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Solid Tumors
N ∕ A
N ∕ Aphase1
phase1
ABBV-525
Small MoleculePharmaceuticalMALT1Oncology
ABBV-525 is an oral small-molecule inhibitor of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1), being investigated in B-cell malignancies.
TargetMALT1
Type of moleculeSmall Molecule
ABBV-525 is an oral small-molecule inhibitor of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1), being investigated in B-cell malignancies.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Hematologic Tumors
N ∕ A
N ∕ Aphase1
phase1
ABBV-453
Small MoleculePharmaceuticalOncologyBcl-2
ABBV-453 is an oral B-cell lymphoma 2 (BCL-2) inhibitor being investigated in relapsed or refractory (R/R) multiple myeloma (MM).
TargetBcl-2
Type of moleculeSmall Molecule
ABBV-453 is an oral B-cell lymphoma 2 (BCL-2) inhibitor being investigated in relapsed or refractory (R/R) multiple myeloma (MM).
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Relapsed ∕ Refractory Multiple Myeloma
N ∕ A
N ∕ Aphase1
phase1
Armour Thyroid
Large MoleculePharmaceuticalT3T4Other Specialties
Armour Thyroid being investigated for treatment of hypothyroidism.
TargetT3T4
Type of moleculeLarge Molecule
Pronunciation
Armour Thyroid being investigated for treatment of hypothyroidism.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Hypothyroidism
N ∕ A
N ∕ Aphase3
phase3
Aztreonam / Avibactam
Small MoleculePharmaceuticalPBP3Other Specialties
Aztreonam / Avibactam is a combination being investigated for treatment of complicated gram-negative bacterial infections.
TargetPBP3
Type of moleculeSmall Molecule
Pronunciation
Aztreonam / Avibactam is a combination being investigated for treatment of complicated gram-negative bacterial infections.
ALPN-101, a first-in-class dual CD28/ICOS antagonist. CD28 and ICOS are key costimulatory molecules that likely play critical roles in multiple autoimmune and inflammatory diseases. ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways with demonstrated efficacy in multiple preclinical disease models, superior to blockade of either pathway alone. AbbVie and Alpine have entered into an exclusive worldwide option and license agreement for ALPN-101.
TargetDual CD28-ICOS Antagonist
Type of moleculeBiologic
ALPN-101, a first-in-class dual CD28/ICOS antagonist. CD28 and ICOS are key costimulatory molecules that likely play critical roles in multiple autoimmune and inflammatory diseases. ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways with demonstrated efficacy in multiple preclinical disease models, superior to blockade of either pathway alone. AbbVie and Alpine have entered into an exclusive worldwide option and license agreement for ALPN-101.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Systemic Lupus Erythematosus (SLE)
Global
Globalphase2
phase2
ABBV-552
Small MoleculePharmaceuticalNeuroscienceSV2A
ABBV-552 is an SV2A modulator which is being evaluated to target nerve terminals to enhance synaptic efficiency. The mechanism is being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders.
TargetSV2A
Type of moleculeSmall Molecule
ABBV-552 is an SV2A modulator which is being evaluated to target nerve terminals to enhance synaptic efficiency. The mechanism is being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Alzheimer's Disease
N ∕ A
N ∕ Aphase2
phase2
TTX-030
BiologicPharmaceuticalOncologyCD39Partner Asset
TTX-030 is a monoclonal antibody that inhibits the activity of CD39.
Trishula Therapeutics is leading the development of TTX-030 through the completion of Phase 1b studies, after which AbbVie has an exclusive option to lead global development and commercial activities. Trishula retains an option to co-develop TTX-030 in the U.S.
TargetCD39
Type of moleculeBiologic
TTX-030 is a monoclonal antibody that inhibits the activity of CD39.
Trishula Therapeutics is leading the development of TTX-030 through the completion of Phase 1b studies, after which AbbVie has an exclusive option to lead global development and commercial activities. Trishula retains an option to co-develop TTX-030 in the U.S.
AGN-193408, a novel analogue of prostaglandin that increases the outflow of aqueous fluid from the eye and lowers intraocular pressure (IOP), is being investigated for the treatment of open angle glaucoma (OAG) and occular hypertension (OHT).
TargetPGF2 alpha receptor
Type of moleculeIntracameral Implant
AGN-193408, a novel analogue of prostaglandin that increases the outflow of aqueous fluid from the eye and lowers intraocular pressure (IOP), is being investigated for the treatment of open angle glaucoma (OAG) and occular hypertension (OHT).
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Open Angle Glaucoma
N ∕ A
N ∕ Aphase2
phase2
Ocular Hypertension
N ∕ A
N ∕ Aphase2
phase2
ABBV-668
ImmunologyRIPK1Small MoleculePharmaceutical
ABBV-668 is an inhibitor of receptor-interacting protein kinase 1 (RIPK1) being investigated for the treatment of ulcerative colitis.
TargetRIPK1
Type of moleculeSmall Molecule
ABBV-668 is an inhibitor of receptor-interacting protein kinase 1 (RIPK1) being investigated for the treatment of ulcerative colitis.
CUG-252, is an engineered IL-2 mutein designed to selectively activate and expand immune-suppressive Treg cells while reducing undesired IL-2 activity on other IL-2 receptor expressing cells. CUG-252 developed by Cugene through Phase 1b; AbbVie has the option to obtain an exclusive license to CUG-252.
TargetIL-2 Mutein
Type of moleculeBiologic
CUG-252, is an engineered IL-2 mutein designed to selectively activate and expand immune-suppressive Treg cells while reducing undesired IL-2 activity on other IL-2 receptor expressing cells. CUG-252 developed by Cugene through Phase 1b; AbbVie has the option to obtain an exclusive license to CUG-252.
CLF065 is a long-acting GLP2R agonist being evaluated for inflammatory bowel disease. CLF065 developed by Calibr, a division of Scripps Research, in a first-in-patient trial; AbbVie holds option for additional development.
TargetGLP-2 agonist
Type of moleculeBiologic
CLF065 is a long-acting GLP2R agonist being evaluated for inflammatory bowel disease. CLF065 developed by Calibr, a division of Scripps Research, in a first-in-patient trial; AbbVie holds option for additional development.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
IBD
N ∕ A
N ∕ Aphase1
phase1
ABBV-RGX-314
BiologicPharmaceuticalEye CarePartner AssetVEGF
ABBV-RGX-314 is a potential one-time gene therapy being investigated for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. ABBV-RGX-314 is being co-developed by REGENEXBIO and AbbVie.
TargetVEGF
Type of moleculeBiologic
ABBV-RGX-314 is a potential one-time gene therapy being investigated for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. ABBV-RGX-314 is being co-developed by REGENEXBIO and AbbVie.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
wet AMD (subretinal)
N ∕ A
N ∕ Aphase3
phase3
wet AMD (suprachoroidal)
N ∕ A
N ∕ Aphase2
phase2
Diabetic Retinopathy (suprachoroidal)
N ∕ A
N ∕ Aphase2
phase2
ABBV-101
BTKSmall MoleculePharmaceuticalOncology
ABBV-101 is a small molecule degrader of Bruton's tyrosine kinase (BTK) being investigated for the treatment of B-cell malignancies.
TargetBTK
Type of moleculeSmall Molecule
ABBV-101 is a small molecule degrader of Bruton's tyrosine kinase (BTK) being investigated for the treatment of B-cell malignancies.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Hematologic Tumors
N ∕ A
N ∕ Aphase1
phase1
BoNTE
Large MoleculePharmaceuticalSNARE ProteinsAesthetics
BoNTE is a toxin being investigated for treatment of glabellar lines.
TargetSNARE Proteins
Type of moleculeLarge Molecule
Pronunciation
BoNTE is a toxin being investigated for treatment of glabellar lines.
Monoclonal antibody against the inflammatory form of stem cell factor (SCF). OpSCF specifically targets SCF248, an isoform of SCF, which is known to drive inflammation. Developed in partnership with Opsidio.
TargetSCF248
Type of moleculeBiologic
Monoclonal antibody against the inflammatory form of stem cell factor (SCF). OpSCF specifically targets SCF248, an isoform of SCF, which is known to drive inflammation. Developed in partnership with Opsidio.
Epcoritamab (Gen3013; DuoBody®-CD3xCD20) is bispecific antibody created using Genmab's proprietary DuoBody® technology. It is designed to target CD3, which is expressed on T cells and is part of the T cell receptor signaling complex, and CD20, a clinically well validated therapeutic target. CD20 is expressed on a majority of B cell malignancies, including chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), B-cell Non-Hodgkin lymphoma (NHL), and relapsed/refractory CLL and Richter's Syndrome. AbbVie and Genmab will participate in the joint development and commercialization of Epcoritamab (Gen3013). Genmab will book net sales in the U.S. and Japan and receive tiered royalties on remaining global sales.
TargetDuoBody-CD3xCD20
Type of moleculeBiologic
Pronunciation
Epcoritamab (Gen3013; DuoBody®-CD3xCD20) is bispecific antibody created using Genmab's proprietary DuoBody® technology. It is designed to target CD3, which is expressed on T cells and is part of the T cell receptor signaling complex, and CD20, a clinically well validated therapeutic target. CD20 is expressed on a majority of B cell malignancies, including chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), B-cell Non-Hodgkin lymphoma (NHL), and relapsed/refractory CLL and Richter's Syndrome. AbbVie and Genmab will participate in the joint development and commercialization of Epcoritamab (Gen3013). Genmab will book net sales in the U.S. and Japan and receive tiered royalties on remaining global sales.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Relapsed ∕ Refractory Diffuse Large B-cell Lymphoma
Elezanumab (ABT-555) is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries and acute ischemic stroke.
TargetRGMa
Type of moleculeBiologic
Pronunciation
Elezanumab (ABT-555) is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries and acute ischemic stroke.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Spinal Cord Injury
N ∕ A
N ∕ Aphase2
phase2
Acute Ischemic Stroke
N ∕ A
N ∕ Aphase2
phase2
ABBV-932
Small MoleculePharmaceuticalDRD2 ∕ DRD3 ModulatorNeurosciencePartner Asset
ABBV 932 is a selective D3 dopamine receptor modulator being investigated for the treatment of bipolar depression and generalized anxiety disorder. Developed in partnership with Gedeon Richter.
TargetDRD2 ∕ DRD3 Modulator
Type of moleculeSmall Molecule
ABBV 932 is a selective D3 dopamine receptor modulator being investigated for the treatment of bipolar depression and generalized anxiety disorder. Developed in partnership with Gedeon Richter.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Bipolar Depression
N ∕ A
N ∕ Aphase1
phase1
ABBV-1882
anti-PD1 and anti-a4b7 mAbBiologicPharmaceuticalOther Specialties
ABBV-1882 is a combination of ABBV-181 (budigalimab, anti-PD1) and ABBV-382 (anti-a4B7 mAb) being investigated as a regimen for HIV viral control off antiretroviral therapy (ART).
Targetanti-PD1 and anti-a4b7 mAb
Type of moleculeBiologic
ABBV-1882 is a combination of ABBV-181 (budigalimab, anti-PD1) and ABBV-382 (anti-a4B7 mAb) being investigated as a regimen for HIV viral control off antiretroviral therapy (ART).
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
HIV
N ∕ A
N ∕ Aphase2
phase2
ABBV-1088
PINK1Small MoleculePharmaceuticalNeuroscience
ABBV-1088 is selective PINK1 activator being evaluated as a potential disease modifying therapy for Parkinson's disease. This compound is designed to address mitochondrial dysfunction which plays a key role in the pathogenesis of Parkinson’s disease.
TargetPINK1
Type of moleculeSmall Molecule
ABBV-1088 is selective PINK1 activator being evaluated as a potential disease modifying therapy for Parkinson's disease. This compound is designed to address mitochondrial dysfunction which plays a key role in the pathogenesis of Parkinson’s disease.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Parkinson's Disease
N ∕ A
N ∕ Aphase1
phase1
ABBV-113
ImmunologySmall MoleculePharmaceuticalNLRX1
ABBV-113 is an oral NLRX1 agonist (a member of the NOD-like receptor family) being investigated for treatment of ulcerative colitis. NLRX1 regulates immunometabolism and inflammation, and its activation may address inflammatory bowel disease (IBD) pathogenesis.
TargetNLRX1
Type of moleculeSmall Molecule
ABBV-113 is an oral NLRX1 agonist (a member of the NOD-like receptor family) being investigated for treatment of ulcerative colitis. NLRX1 regulates immunometabolism and inflammation, and its activation may address inflammatory bowel disease (IBD) pathogenesis.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Ulcerative Colitis
N ∕ A
N ∕ Aphase2
phase2
ABBV-8736
BiologicImmunologyPharmaceuticalTREM1
ABBV-8736 is an anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody being investigated for treatment of inflammatory bowel disease (IBD). TREM1 has been identified as a key disease driver gene in IBD, upstream of known inflammatory pathways.
TargetTREM1
Type of moleculeBiologic
ABBV-8736 is an anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody being investigated for treatment of inflammatory bowel disease (IBD). TREM1 has been identified as a key disease driver gene in IBD, upstream of known inflammatory pathways.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
IBD
N ∕ A
N ∕ Aphase1
phase1
Emraclidine
M4 PAMSmall MoleculePharmaceuticalNeuroscience
Emraclidine is an orally available muscarinic M4 Receptor (PAM) being investigated for the treatment of schizophrenia and other forms of psychosis.
TargetM4 PAM
Type of moleculeSmall Molecule
Emraclidine is an orally available muscarinic M4 Receptor (PAM) being investigated for the treatment of schizophrenia and other forms of psychosis.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Schizophrenia
N ∕ A
N ∕ Aphase2
phase2
Alzheimer's Disease Psychosis
N ∕ A
N ∕ Aphase1
phase1
Tavapadon
Small MoleculeD1 ∕ D5 Partial AgonistPharmaceuticalNeuroscience
Tavapadon is an orally active dopamine D1/D5 receptor selective partial agonist being investigated for the treatment of Parkinson's disease (both monotherapy and adjunctive).
TargetD1 ∕ D5 Partial Agonist
Type of moleculeSmall Molecule
Tavapadon is an orally active dopamine D1/D5 receptor selective partial agonist being investigated for the treatment of Parkinson's disease (both monotherapy and adjunctive).
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Parkinson's Disease
N ∕ A
N ∕ Aphase3
phase3
Razpipadon (CVL-871)
Small MoleculeD1 ∕ D5 Partial AgonistPharmaceuticalNeuroscience
Razpipadon (CVL-871) is an orally active dopamine D1/D5 receptor selective partial agonist being investigated for the treatment of dementia-related apathy.
TargetD1 ∕ D5 Partial Agonist
Type of moleculeSmall Molecule
Razpipadon (CVL-871) is an orally active dopamine D1/D5 receptor selective partial agonist being investigated for the treatment of dementia-related apathy.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Dementia-related Apathy
N ∕ A
N ∕ Aphase2
phase2
Icalcaprant (CVL-354)
Small MoleculePharmaceuticalNeuroscienceKOR antagonist
Icalcaprant (CVL-354) is a kappa opioid receptor (KOR) antagonist being investigated for treatment of major depressive disorder (MDD).
TargetKOR antagonist
Type of moleculeSmall Molecule
Icalcaprant (CVL-354) is a kappa opioid receptor (KOR) antagonist being investigated for treatment of major depressive disorder (MDD).
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Major Depressive Disorder
N ∕ A
N ∕ Aphase1
phase1
SKYRIZI
BiologicImmunologyIL-23Pharmaceutical
SKYRIZI® (risankizumab) (ABBV-066) is an anti-IL-23 antibody approved for the treatment of multiple inflammatory diseases, including psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease.
TargetIL-23
Type of moleculeBiologic
Pronunciation
SKYRIZI® (risankizumab) (ABBV-066) is an anti-IL-23 antibody approved for the treatment of multiple inflammatory diseases, including psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease.
Livmoniplimab (ABBV-151) is a humanized monoclonal antibody inhibitor of GARP- TGF-β1 being investigated for the treatment of cancer. Developed in partnership with argenx. Budigalimab (ABBV-181) is an anti-PD1 humanized monoclonal antibody that is being developed for combinations with other AbbVie molecules for solid tumors and hematologic malignancies.
TargetGARP-TGF-β1
Type of moleculeBiologic
Livmoniplimab (ABBV-151) is a humanized monoclonal antibody inhibitor of GARP- TGF-β1 being investigated for the treatment of cancer. Developed in partnership with argenx. Budigalimab (ABBV-181) is an anti-PD1 humanized monoclonal antibody that is being developed for combinations with other AbbVie molecules for solid tumors and hematologic malignancies.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Liver
N ∕ A
N ∕ Aphase2
phase2
Solid Tumors
N ∕ A
N ∕ Aphase2
phase2
Non-Small Cell Lung Cancer
N ∕ A
N ∕ Aphase2
phase2
Etentamig (ABBV-383)
CD3-BCMABiologicPharmaceuticalOncology
Etentamig (ABBV-383) is a BCMA x CD3 T-cell engaging bispecifc antibody being studied in relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy.
TargetCD3-BCMA
Type of moleculeBiologic
Etentamig (ABBV-383) is a BCMA x CD3 T-cell engaging bispecifc antibody being studied in relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Multiple Myeloma
N ∕ A
N ∕ Aphase3
phase3
Immunoglobulin Light Chain (AL) Amyloidosis
N ∕ A
N ∕ Aphase1
phase1
Teliso-V (ABBV-399)
Biologicc-MetPharmaceuticalOncology
Teliso-V (telisotuzumab vedotin) (ABBV-399) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat non-small cell lung cancer (NSCLC).
Targetc-Met
Type of moleculeBiologic
Pronunciation
Teliso-V (telisotuzumab vedotin) (ABBV-399) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat non-small cell lung cancer (NSCLC).
SKYRIZI® (risankizumab) (ABBV-066) is an anti-IL-23 antibody. ABBV-382 is an anti-a4B7 mAb. Risankizumab + ABBV-382 are being investigated as a combination therapy for the treatment of Crohn's disease.
TargetIL-23 + anti-a4b7 mAb
Type of moleculeBiologic
SKYRIZI® (risankizumab) (ABBV-066) is an anti-IL-23 antibody. ABBV-382 is an anti-a4B7 mAb. Risankizumab + ABBV-382 are being investigated as a combination therapy for the treatment of Crohn's disease.
SKYRIZI® (risankizumab) (ABBV-066) is an anti-IL-23 antibody. Lutikizumab (ABT-981) is an IL-1a/1b antagonist. Risankizumab + lutikizumab are being investigated as a combination therapy for the treatment of Crohn's disease.
TargetIL-23 + IL-1a ∕ 1b
Type of moleculeBiologic
SKYRIZI® (risankizumab) (ABBV-066) is an anti-IL-23 antibody. Lutikizumab (ABT-981) is an IL-1a/1b antagonist. Risankizumab + lutikizumab are being investigated as a combination therapy for the treatment of Crohn's disease.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Crohn's Disease
N ∕ A
N ∕ Aphase2
phase2
Fosigotifator (ABBV-CLS-7262)
eIF2BSmall MoleculePharmaceuticalNeuroscience
Fosigotifator (ABBV-CLS-7262) is an eIF2B activator being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS) and Vanishing White Matter disease (VWM). Calico is responsible for research and early development and will advance collaboration projects into Phase 2a, including Fosigotifator. AbbVie will continue to support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities.
TargeteIF2B
Type of moleculeSmall Molecule
Fosigotifator (ABBV-CLS-7262) is an eIF2B activator being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS) and Vanishing White Matter disease (VWM). Calico is responsible for research and early development and will advance collaboration projects into Phase 2a, including Fosigotifator. AbbVie will continue to support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Amyotrophic Lateral Sclerosis (ALS)
N ∕ A
N ∕ Aphase2
phase2
Vanishing White Matter disease (VWM)
N ∕ A
N ∕ Aphase1
phase1
VENCLEXTA
Small MoleculePharmaceuticalOncologyBcl-2
VENCLEXTA™ (US), Venclyxto (EU) (venetoclax) (ABT-199) is a selective, oral small molecule Bcl-2 inhibitor being investigated for the treatment of multiple cancers.
TargetBcl-2
Type of moleculeSmall Molecule
Pronunciation
VENCLEXTA™ (US), Venclyxto (EU) (venetoclax) (ABT-199) is a selective, oral small molecule Bcl-2 inhibitor being investigated for the treatment of multiple cancers.
ABBV-514 is an anti-chemokine C-C motif receptor 8 (CCR8) antibody that is being investigated for the treatment of relapsed non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.
TargetCCR8
Type of moleculeBiologic
ABBV-514 is an anti-chemokine C-C motif receptor 8 (CCR8) antibody that is being investigated for the treatment of relapsed non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.
VYALEV™ (US), Produodopa (EU) (ABBV-951) is a subcutaneous delivery of Levodopa/Carbidopa being investigated for the treatment of Parkinson’s disease.
TargetDopamine Receptor
Type of moleculeSmall Molecule
VYALEV™ (US), Produodopa (EU) (ABBV-951) is a subcutaneous delivery of Levodopa/Carbidopa being investigated for the treatment of Parkinson’s disease.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Parkinson's Disease
US , JA , EU
US , JA , EUapproved
approved
Darigabat
Small MoleculePharmaceuticalNeuroscienceGABA-A PAM
Darigabat is an orally selective gamma-aminobutyric acid type A (GABA-A) receptor being investigated for the treatment of focal epilepsy and panic disorder.
TargetGABA-A PAM
Type of moleculeSmall Molecule
Darigabat is an orally selective gamma-aminobutyric acid type A (GABA-A) receptor being investigated for the treatment of focal epilepsy and panic disorder.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Panic Disorder
N ∕ A
N ∕ Aphase2
phase2
BOTOX
Large MoleculePharmaceuticalNeuroscienceSNARE Proteins
Neurotoxin being investigated for Essential Tremor, a disorder that causes involuntary and rhythmic shaking and Episodic Migraine, characterized by those with less than 15 headache days per month.
TargetSNARE Proteins
Type of moleculeLarge Molecule
Pronunciation
Neurotoxin being investigated for Essential Tremor, a disorder that causes involuntary and rhythmic shaking and Episodic Migraine, characterized by those with less than 15 headache days per month.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Episodic Migraine Prophylaxis
N ∕ A
N ∕ Aphase3
phase3
Essential Tremor
N ∕ A
N ∕ Aphase2
phase2
BOTOX
Large MoleculePharmaceuticalSNARE ProteinsOther Specialties
Neurotoxin being investigated for Interstitial Cystitis / Bladder Pain Syndrome, a chronic bladder condition that causes pain and/or discomfort in the bladder or pelvic region.
TargetSNARE Proteins
Type of moleculeLarge Molecule
Pronunciation
Neurotoxin being investigated for Interstitial Cystitis / Bladder Pain Syndrome, a chronic bladder condition that causes pain and/or discomfort in the bladder or pelvic region.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
IC BPS
N ∕ A
N ∕ Aphase2
phase2
BOTOX
Large MoleculePharmaceuticalSNARE ProteinsAesthetics
BOTOX® is a neurotoxin being investigated for treatment of multiple conditions.
TargetSNARE Proteins
Type of moleculeLarge Molecule
Pronunciation
BOTOX® is a neurotoxin being investigated for treatment of multiple conditions.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Platysma Prominence
US
USapproved
approved
Masseter Prominence
CNN ∕ A
CNapproved
N ∕ Aphase3
approved
phase3
Temab-A (ABBV-400)
BiologiccMET + Topo-1 ADCPharmaceuticalOncology
Temab-A (telisotuzumab adizutecan) (ABBV-400) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and gastroesophageal adenocarcinoma (GEA).
TargetcMET + Topo-1 ADC
Type of moleculeBiologic
Temab-A (telisotuzumab adizutecan) (ABBV-400) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and gastroesophageal adenocarcinoma (GEA).
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Colorectal Cancer
N ∕ A
N ∕ Aphase2
phase2
Solid Tumors
N ∕ A
N ∕ Aphase1
phase1
RINVOQ
ImmunologySmall MoleculeJAK1Pharmaceutical
RINVOQ™ (upadacitinib) (ABT-494) is a JAK1 selective inhibitor being investigated to treat alopecia areata, ankylosing spondylitis, atopic dermatitis, axial SpA, Crohn's disease, giant cell arteritis, hidradenitis suppurativa (HS), psoriatic arthritis, rheumatoid arthritis, systemic lupus erthematosus (SLE), Takayasu arteritis, ulcerative colitis and vitiligo.
TargetJAK1
Type of moleculeSmall Molecule
Pronunciation
RINVOQ™ (upadacitinib) (ABT-494) is a JAK1 selective inhibitor being investigated to treat alopecia areata, ankylosing spondylitis, atopic dermatitis, axial SpA, Crohn's disease, giant cell arteritis, hidradenitis suppurativa (HS), psoriatic arthritis, rheumatoid arthritis, systemic lupus erthematosus (SLE), Takayasu arteritis, ulcerative colitis and vitiligo.
ELAHERE® (mirvetuximab soravtansine) is a folate receptor alpha-targeting antibody drug conjugate (ADC) with accelerated approval in 2L+ platinum resistant ovarian cancer.
TargetFR-alpha + DM4 maytansinoid
Type of moleculeBiologic
ELAHERE® (mirvetuximab soravtansine) is a folate receptor alpha-targeting antibody drug conjugate (ADC) with accelerated approval in 2L+ platinum resistant ovarian cancer.
Potential Indication
Region
Phase 1Phase 2Phase 3
Status
Status
Platinum-Resistant Ovarian Cancer
N ∕ A
N ∕ Aapproved
approved
Platinum-Sensitive Ovarian Cancer
N ∕ A
N ∕ Aphase3
phase3
Tropoelastin
Facial AestheticsDeviceSkin DeformitiesAesthetics
Tropoelastin is an injectable gel comprised of a cross-linked tropoelastin matrix under investigation for the correction of atrophic scars.
TargetSkin Deformities
Type of moleculeFacial Aesthetics
Tropoelastin is an injectable gel comprised of a cross-linked tropoelastin matrix under investigation for the correction of atrophic scars.
Potential Indication
Region
FeasibilityDevelopmentConfirmation
Status
Status
Atrophic Scars
N A
N Aconfirmation
confirmation
Resonic
Body ContouringDeviceCelluliteAesthetics
Resonic is a Rapid Acoustic Pulse device being investigated for improvement in the appearance of cellulite.
TargetCellulite
Type of moleculeBody Contouring
Pronunciation
Resonic is a Rapid Acoustic Pulse device being investigated for improvement in the appearance of cellulite.
HArmonyCa™ is a dual-action hybrid injectable, with Calcium Hydroxyapatite and cross-linked Hyaluronic Acid, being investigated to restore mid facial volume.
TargetFacial Contouring
Type of moleculeFacial Aesthetics
Pronunciation
HArmonyCa™ is a dual-action hybrid injectable, with Calcium Hydroxyapatite and cross-linked Hyaluronic Acid, being investigated to restore mid facial volume.